GLPwatch
Papers (10401)
Page 66 of 174, ranked by citation count.
- A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder.
- Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
- The GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats.
- Exendin-4 protects rat islets against loss of viability and function induced by brain death.
- Exendin-4 protects HUVECs from tunicamycin-induced apoptosis via inhibiting the IRE1a/JNK/caspase-3 pathway.
- Cardiovascular effects of incretins in diabetes.
- Exenatide in acute ischemic stroke.
- Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease?
- Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
- Neutral effect of exenatide on serum testosterone in men with type 2 diabetes mellitus: A prospective cohort.
- Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.
- Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6.
- Preliminary Evidence Suggests That a 12-Week Treatment with Tirzepatide Plus Low-Energy Ketogenic Therapy Is More Effective than Its Combination with a Low-Calorie Diet in Preserving Fat-Free Mass, Muscle Strength, and Resting Metabolic Rate in Patients with Obesity.
- Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.
- Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
- Treatment with exenatide in acute ischemic stroke trial protocol: A prospective, randomized, open label, blinded end-point study of exenatide vs. standard care in post stroke hyperglycemia.
- Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.
- Sol-gel transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus.
- Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction.
- The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis.
- Recent advances in peptide-based therapies for obesity and type 2 diabetes.
- Exenatide extended-release: a review of its use in type 2 diabetes mellitus.
- Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats.
- A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes.
- Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.
- Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care.
- Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes.
- Lower Risk of Postoperative Complications and Rotator Cuff Retear Associated With Semaglutide Use in Patients with Type II Diabetes Mellitus Undergoing Arthroscopic Rotator Cuff Repair.
- Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.
- Dual GLP-1 and GIP Agonist Tirzepatide Exerted Neuroprotective Action in a Parkinson's Disease Rat Model.
- Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic.
- Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.
- Key takeaways from the updated multidisciplinary European MASLD guidelines.
- [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus].
- The glucagon-like peptide-1 (GLP-1) analog exenatide ameliorates intrauterine adhesions in mice.
- Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet.
- A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.
- Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data.
- Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.
- Cost effectiveness of liraglutide in type II diabetes: a systematic review.
- Exendin-4 does not modify growth or apoptosis of human colon cancer cells.
- Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
- The impact of the glucagon-like peptide 1 receptor agonist liraglutide on the streptozotocin-induced diabetic mouse kidney proteome.
- Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review.
- Liraglutide promotes the angiogenic ability of human umbilical vein endothelial cells through the JAK2/STAT3 signaling pathway.
- The Glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome.
- Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
- Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network.
- High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.
- Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using <sup>111</sup>In-exendin-4 SPECT/CT imaging and the perspective of mitochondrial involvements.
- Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.
- The effect of obesity pharmacotherapy on body composition, including muscle mass.
- Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.
- Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect.
- The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
- Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.
- A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.
- Liraglutide and Naringenin relieve depressive symptoms in mice by enhancing Neurogenesis and reducing inflammation.
- A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.
- Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.